A Safety Study of SGN-LIV1A in Breast Cancer Patients
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2 Positive Breast Neoplasms|Hormone Receptor Positive Breast Neoplasms|Triple Negative Breast Neoplasms|HER2 Mutations Breast Neoplasms
Interventions: DRUG: ladiratuzumab vedotin|DRUG: Trastuzumab
Sponsor: Seagen Inc.